These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 7617864)

  • 21. Nondiffuse fatty change of the liver: discerning pseudotumor on MR images enhanced with ferumoxides-initial observations.
    Hirohashi S; Ueda K; Uchida H; Ono W; Takahama J; Takewa M; Kitano S; Ohishi H
    Radiology; 2000 Nov; 217(2):415-20. PubMed ID: 11058637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of focal liver lesions with superparamagnetic iron oxide: value of STIR and SE imaging.
    Halavaara JT; Lamminen AE; Bondestam S; Standertskjöld-Nordenstam CG; Hamberg LM
    J Comput Assist Tomogr; 1994; 18(6):897-904. PubMed ID: 7962796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of dynamic gadolinium-enhanced and ferumoxides-enhanced MRI of the liver on high- and low-field scanners.
    Limanond P; Raman SS; Sayre J; Lu DS
    J Magn Reson Imaging; 2004 Oct; 20(4):640-7. PubMed ID: 15390231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRI of liver: a comparison of CNR enhancement using high dose and low dose ferumoxide infusion in patients with colorectal liver metastases.
    Scott J; Ward J; Guthrie JA; Wilson D; Robinson PJ
    Magn Reson Imaging; 2000 Apr; 18(3):297-303. PubMed ID: 10745139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical results with Resovist: a phase 2 clinical trial.
    Reimer P; Rummeny EJ; Daldrup HE; Balzer T; Tombach B; Berns T; Peters PE
    Radiology; 1995 May; 195(2):489-96. PubMed ID: 7724772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic MR imaging using ferumoxides: prospective evaluation with surgical and intraoperative sonographic confirmation in 25 cases.
    Raman SS; Lu DS; Chen SC; Sayre J; Eilber F; Economou J
    AJR Am J Roentgenol; 2001 Oct; 177(4):807-12. PubMed ID: 11566677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative detection of malignant hepatic tumors: comparison of combined methods of MR imaging with combined methods of CT.
    Kondo H; Kanematsu M; Hoshi H; Murakami T; Kim T; Hori M; Matsuo M; Nakamura H
    AJR Am J Roentgenol; 2000 Apr; 174(4):947-54. PubMed ID: 10749228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties.
    Kopp AF; Laniado M; Dammann F; Stern W; Grönewäller E; Balzer T; Schimpfky C; Claussen CD
    Radiology; 1997 Sep; 204(3):749-56. PubMed ID: 9280254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing Levovist-enhanced pulse inversion harmonic imaging and ferumoxides-enhanced MR imaging of hepatic metastases.
    Del Frate C; Zuiani C; Londero V; Como G; Bazzocchi M; Mortele K; Ros PR
    AJR Am J Roentgenol; 2003 May; 180(5):1339-46. PubMed ID: 12704048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MR imaging of the liver and spleen: a comparison of the effects on signal intensity of two superparamagnetic iron oxide agents.
    Chen F; Ward J; Robinson PJ
    Magn Reson Imaging; 1999 May; 17(4):549-56. PubMed ID: 10231181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of colorectal liver metastases: prospective comparison of unenhanced and ferumoxides-enhanced magnetic resonance imaging at 1.5 T, dual-phase spiral CT, and spiral CT during arterial portography.
    Lencioni R; Donati F; Cioni D; Paolicchi A; Cicorelli A; Bartolozzi C
    MAGMA; 1998 Dec; 7(2):76-87. PubMed ID: 9951768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Superparamagnetic iron oxide particles: what value has the T1 effect in the MR diagnosis of focal liver lesions?].
    Urhahn R; Adam G; Busch N; Chen JH; Euringer W; Günther RW
    Rofo; 1996 Oct; 165(4):364-70. PubMed ID: 8963049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents.
    Ba-Ssalamah A; Schima W; Schmook MT; Linnau KF; Schibany N; Helbich T; Reimer P; Laengle F; Wrba F; Kurtaran A; Ryan M; Mann FA
    AJR Am J Roentgenol; 2002 Dec; 179(6):1447-56. PubMed ID: 12438034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging.
    Bellin MF; Zaim S; Auberton E; Sarfati G; Duron JJ; Khayat D; Grellet J
    Radiology; 1994 Dec; 193(3):657-63. PubMed ID: 7972804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic MRI with SPIO: detection and characterization of focal liver lesions.
    Reimer P; Tombach B
    Eur Radiol; 1998; 8(7):1198-204. PubMed ID: 9724439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of focal liver lesions in unenhanced and ferucarbotran-enhanced magnetic resonance imaging: a comparison of T2-weighted breath-hold and respiratory-triggered sequences.
    Rief M; Wagner M; Franiel T; Bresan V; Taupitz M; Klessen C; Hamm B; Asbach P
    Magn Reson Imaging; 2009 Nov; 27(9):1223-9. PubMed ID: 19520538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ring enhancement in ultrasmall superparamagnetic iron oxide MR imaging: a potential new sign for characterization of liver lesions.
    Mergo PJ; Helmberger T; Nicolas AI; Ros PR
    AJR Am J Roentgenol; 1996 Feb; 166(2):379-84. PubMed ID: 8553952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined use of MR contrast agents for evaluating liver disease.
    Ward J; Robinson PJ
    Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):767-802, vi. PubMed ID: 11694437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver imaging with ferumoxides (Feridex): fundamentals, controversies, and practical aspects.
    Clément O; Siauve N; Cuénod CA; Frija G
    Top Magn Reson Imaging; 1998 Jun; 9(3):167-82. PubMed ID: 9621405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Superparamagnetic iron oxide particles (SH U 555 A): evaluation of efficacy in three doses for hepatic MR imaging.
    Shamsi K; Balzer T; Saini S; Ros PR; Nelson RC; Carter EC; Tollerfield S; Niendorf HP
    Radiology; 1998 Feb; 206(2):365-71. PubMed ID: 9457187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.